For patients with metastatic castration-resistant prostate cancer (mCRPC), no reliable
biomarkers for predicting therapeutic response or assisting in treatment selection and …

Background To assess which parameters of [68Ga] Ga‐PSMA‐11 positron emission
tomography (PSMA‐PET) predict response to systemic therapies in metastatic (m) castration …

We aimed to evaluate the role of prostate-specific membrane antigen (PSMA) PET/CT for
response assessment and outcome prediction in patients with metastatic castration-resistant …

Abstract Purpose To compare the Response Evaluation Criteria in Solid Tumors (RECIST)
1.1, the adapted Prostate Cancer Working Group Criteria 3 (aPCWG3), the adapted Positron …

Our objective was to develop version 1.0 of a novel framework for response evaluation
criteria in prostate-specific membrane antigen (PSMA) PET/CT (RECIP) and a composite …

Purpose The first aim of this study was to evaluate 68 Ga-PSMA HBED-CC conjugate 11
positron emission tomography (PSMA PET) parameters for assessment of response to 177 …

Purpose To evaluate the use of 68 Ga-PSMA PET/CT for monitoring response to 177 Lu-617
PSMA radioligand therapy in patients with metastatic castrate-resistant prostate cancer …

Background Treatment response is traditionally monitored using prostate-specific antigen
(PSA) and conventional imaging in patients with metastatic prostate cancer (mPCa) …

We aimed to evaluate the role of PET targeting the prostate-specific membrane antigen
(PSMA) for response assessment in metastatic prostate cancer (PCa) patients treated with …

This study was performed to assess the prognostic utility of conventional biochemical and
imaging response criteria and 68Ga-PSMA11 PET–adapted or–specific systems regarding …